PMV Pharmaceuticals Announces Underwritten Offering of Stock and Warrants

What Happened
PMV Pharmaceuticals, Inc. announced on August 31, 2026 that it entered into an underwriting agreement with TD Securities (USA) LLC for an underwritten public offering expected to close on September 2, 2026. The offering consists of 22,055,000 shares of common stock and 19,900,000 pre‑funded warrants, each sold with an accompanying common stock warrant; the offering will include a total of 41,955,000 common stock warrants. The combined offering price is $1.21 per share + warrant and $1.20999 per pre‑funded warrant + warrant. The company estimates net proceeds of approximately $47.0 million after fees and expenses.

Key Details

• Offering size and price: 22,055,000 common shares; 19,900,000 pre‑funded warrants; 41,955,000 accompanying common stock warrants. Combined price per unit: $1.21 (shares) / $1.20999 (pre‑funded units).
• Warrant economics: Pre‑funded warrants exercisable immediately at $0.00001 per share; common stock warrants exercisable immediately, expire 5 years, initial exercise price $1.21.
• Special provisions: Warrants include a reset of the exercise price tied to the company’s public announcement of FDA acceptance for review of the rezatapopt NDA and a potential mandatory cash exercise (up to 50%) if the announcement reflects a positive acceptance decision (between day 30 and day 60 after announcement); ownership cap of 4.99% (or 9.99% if elected) limits exercises.
• Use of proceeds and runway: Company plans to use net proceeds to fund late‑stage development, regulatory submission and commercialization preparation for rezatapopt. PMV says proceeds plus existing cash are expected to fund operations into Q1 2028 (excluding any exercise of the underwriters’ option).

Why It Matters
This financing provides PMV with immediate capital intended to fund late‑stage work and regulatory efforts for rezatapopt, which can be critical to advancing the drug toward potential approval. For investors, the offering will dilute existing shareholders (new shares plus many warrants outstanding) and creates potential future share issuance if warrants are exercised. The FDA‑linked reset and mandatory exercise provisions mean a regulatory event (acceptance of the NDA for review) could change warrant economics and trigger cash exercises or the cancellation of unexercised warrants, affecting both cash inflows and share count.